News and Media

Press Releases

2019

April 24, 2019
Casebia Advances Genetic Engineering with New Tools and Techniques

2018

October 31, 2018
Casebia Therapeutics Expands Leadership Team with Addition of Dr. Adel Nada as Chief Medical Officer

May 30, 2018
Casebia Therapeutics Appoints Amy Jennings to Head its Regulatory Affairs

2017

November 13, 2017
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

September 27, 2017
Casebia Therapeutics Announces License and Collaboration Agreements with Seattle Children’s Research Institute

September 8, 2017
Casebia Therapeutics Strengthens Leadership Team with Two Key Appointments

June 28, 2017
Casebia Therapeutics names Robin A. Walker as Vice President, Head of Legal

May 11, 2017
Casebia Therapeutics Expands Leadership Team

March 14, 2017
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement with MaxCyte

2016

November 1, 2016
Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer

In the News

2018

May 3, 2018
Evolving Industry Partnerships and Investments in Cell and Gene Therapies

2017

September 15, 2017
Boston Business Journal: Casebia Head of Legal Robin Walker named one of the 50 Most Influential People of Color in Healthcare & Life Sciences

Presentations and Abstracts

2019

ASGCT 2019  |  April 29, 2019
Engineering Potent, Small, Chimeric, Synthetic, RNA-Guided Nucleases (sRGN) from Four Uncharacterized Cas9 Genes
Abstract #135  |  Presentation

ASGCT 2019  |  April 29, 2019
Therapeutic Levels of FVIII Generated by CRISPR/Cas9-Mediated In Vivo Genome Editing in Hemophilia A Mice
Abstract #428  |  Presentation

ASGCT 2019  |  April 29, 2019
Lipid Nanoparticle Formulations Optimized for Delivery and In Vivo Gene Editing Using Novel Synthetic RNA Guided Nucleases (sRGN)
Abstract #494  |  Poster

ASGCT 2019  |  April 29, 2019
CRISPR-Based Allele-Specific Editing for the Treatment of Autosomal Dominant Retinitis Pigmentosa (ADRP)
Abstract #550  |  Poster

ASGCT 2019  |  April 29, 2019
CRISPR Cas9/gRNAs Selective Targeting of the GUCY2D Mutant Allele for Autosomal Dominant Cone-Rod Retinal Dystrophy
Abstract #561  |  Poster

ASGCT 2019  |  April 29, 2019
Gene Editing to Enforce FOXP3 Expression and a Rapamycin-Inducible IL-2 Signaling Complex in Human Primary T Cells Allows Selective Expansion of Immunosuppressive Treg-Like Cells
Abstract #660  |  Presentation

ASGCT 2019  |  April 29, 2019
Generation of Selectable, Multi-Edited Allogeneic CD3+ T Cells
Abstract #839  |  Poster

ASGCT 2019  |  April 29, 2019
Efficient and Sustained FOXP3 Locus Editing in Hematopoietic Stem Cells as a Therapeutic Approach for IPEX Syndrome
Abstract #850  |  Poster

ASGCT 2019  |  April 29, 2019
Manufacturing of Gene-Edited, Regulatory-Like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune Disorders
Abstract #857  |  Poster

ASGCT 2019  |  April 29, 2019
CRISPR/Cas9-Engineered Transgenesis of Hematopoietic Stem Cells via NHEJ-Mediated Targeted Integration Retains Engraftment Potential
Abstract #965  |  Presentation

Social Media

We are so grateful to be a part of the #Cambridge community. Thank you to @KendallNow for hosting the #ksqchallenge! It was great to take advantage of the opportunity to engage in some friendly competition and do some good for our community. Can’t wait for next year!

Members of our #Cambridge team are out in force for today's @KendallNow #KSqChallenge! Here's a photo of our two teams - Casebia Cares and Casebia Conquers - getting ready to volunteer on a beautiful spring day. #KendallTogether

See us on Twitter